Pancreatic Cancer Research

ResearcherMedical University of South CarolinaNo recent work listed

Carolyn D. Britten

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5052493398. Sources: ClinicalTrials.gov.

Their work

Papers
2 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper

Papers 2

  1. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-l… Co-author DOI 10.1007/s10637-019-00830-3↗
  2. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. First author DOI 10.1186/s13045-017-0459-2↗

Trials 1

  1. ABC294640 in Treating Patients With Advanced Solid Tumors Principal investigator NCT01488513↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David C. Linehan · 1 shared paper, 2020 · strength 0.09
  2. Andrea J. Bullock · 1 shared paper, 2020 · strength 0.09
  3. Eileen Mary O'Reilly · 1 shared paper, 2020 · strength 0.09
  4. David P. Ryan · 1 shared paper, 2020 · strength 0.09
  5. Maeve Aine Lowery · 1 shared paper, 2020 · strength 0.09
  6. Marcus Smith Noel · 1 shared paper, 2020 · strength 0.09
  7. Brian Matthew Wolpin · 1 shared paper, 2020 · strength 0.09
  8. David J. Cole · 1 shared paper, 2017 · strength 0.06
  9. Chrystal M Paulos · 1 shared paper, 2017 · strength 0.06
  10. Shikhar Mehrotra · 1 shared paper, 2017 · strength 0.06
  11. Mark P. Rubinstein · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.